istock-909045842-peopleimages
peopleimages / iStockphoto.com
9 April 2019Americas

Alnylam and Regeneron unveil RNAi partnership

Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
Americas
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.
Americas
3 February 2026   Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.